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Abstract
Background: Clinical practice guidelines are important for guiding practice, but it is unclear if they are commensurate with
the available evidence.
Methods: We examined guidelines produced by cancer and gynecological societies and organizations and evaluated their
coverage of and stance towards chemotherapy for advanced stage disease among 4 gynecological malignancies (breast,
ovarian, cervical, endometrial cancer) where the evidence for the use of chemotherapy is very different (substantial and
conclusive for breast and ovarian cancer, limited and suggesting no major benefit for cervical and endometrial cancer).
Eligible societies and organizations were identified through systematic internet searches (last update June 2009). Pertinent
websites were scrutinized for presence of clinical practice guidelines, and relative guidelines were analyzed.
Results: Among 224 identified eligible societies and organizations, 69 (31%) provided any sort of guidelines, while
recommendations for chemotherapy on advanced stage gynecological malignancies were available in 20 of them. Only 14
had developed their own guideline, and only 5 had developed guidelines for all 4 malignancies. Use of levels of evidence
and grades of recommendations, and aspects of the production, implementation, and timeliness of the guidelines did not
differ significantly across malignancies. Guidelines on breast and ovarian cancer utilized significantly more randomized trials
and meta-analyses. Guidelines differed across malignancies on their coverage of disease-free survival (p=0.033), response
rates (p=0.024), symptoms relief (p=0.005), quality of life (p=0.001) and toxicity (p=0.039), with breast and ovarian cancer
guidelines typically covering more frequently these outcomes. All guidelines explicitly or implicitly endorsed the use of
chemotherapy.
Conclusions: Clinical practice guidelines are provided by the minority of professional societies and organizations. Available
guidelines tend to recommend chemotherapy even for diseases where the effect of chemotherapy is controversial and
recommendations are based on scant evidence.
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Introduction
Clinical practice guidelines are important for interpreting and
translating research evidence for clinical practice and medical
decision making. As stated by the Institute of Medicine ‘‘guidelines
are systematically defined and evidence-based statements that
reduce undesirable practice variation by discouraging use of
services of questionable value while encouraging use of services
with proven efficacy’’ [1]. However developing reliable, updated
and uniform guidelines requires great care and commitment and
professional organizations often do not offer detailed recommen-
dations for certain diseases or groups of patients [2]. Moreover,
even when guidelines are available, it may be difficult to locate
guidelines developed by diverse organizations [3]. For some
diseases and questions of interest, sufficient and/or good quality
scientific evidence about what to recommend is lacking [4] and
subjective recommendations may sometimes be inconsistent across
guidelines by different societies, or even harmful [5,6]. Even when
extensive, high-quality evidence exists, there is no assurance that
different guidelines make similar recommendations [7] and timely
updates are also essential [8,9], especially when evidence is
changing rapidly. When there are guidelines on the same question
of interest produced by different organizations, discrepancies in
recommendations may generate confusion.
Here we aimed to examine systematically guidelines produced
by professional societies and organizations in the fields of cancer
and gynecological oncology and evaluate in depth guidelines that
address the use of chemotherapy in advanced stage gynecological
malignancies, including breast, ovarian, cervical and endometrial
cancer. All these malignancies are common [10]. Importantly,
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20106they respond differently to chemotherapy, with extensive evidence
and clear benefits demonstrated for breast and ovarian cancer and
questionable benefits, for advanced endometrial and cervical
cancer. Moreover, these malignancies differ a lot in the number of
randomized trials that have been conducted on chemotherapy:
recent meta-analyses have identified 370, 198, 65, and 13
randomized trials on chemotherapy for advanced stage breast,
ovarian, cervical, and endometrial cancer, respectively
[11,12,13,14] and the evidence suggests that chemotherapy can
be useful for advanced breast and ovarian cancer, but net benefits
for hard endpoints (e.g. survival) are limited, if any, for stage III–
IVA cervical cancer, and probably trivial or non-existent for stage
IVB cervical cancer and advanced endometrial cancer
[11,12,13,14]. We performed an extensive search to catalogue
relevant societies and organizations worldwide and examined
which of them provide any sort of clinical practice guidelines
pertinent to chemotherapy for these malignancies. These guide-
lines were then scrutinized to assess and compare their features
and concordance with the available evidence.
Methods
Identification of pertinent societies and organizations
We constructed a database of gynecological and cancer societies
and organizations that might provide guidelines for chemotherapy
in advanced gynecological malignancies. We considered societies
and organizations that were international (with global outlook),
intercontinental (including two or more countries in a continent),
or national belonging to one of the top 20 countries with the
highest human development index [15]. We did not consider
private institutions, regional or local societies, regardless of
whether they might have produced guidelines or not. Organiza-
tions could be either professional societies for specialists or other
public not-for-profit organizations.
We performed internet searches in Google and Yahoo
(completed in June 2009). Initially we made 624 different searches
with each engine and the first 100 results for each search were
scrutinized. The 624 searches pertain to all the possible
combinations of 8 subject matter terms (‘‘cancer’’, ‘‘oncology’’,
‘‘medical oncology’’, ‘‘radiation oncology’’, ‘‘surgical oncology’’,
‘‘cancer research’’, ‘‘gynecology’’, ‘‘gynecologic oncology’’), three
terms for type of entity (‘‘society’’, ‘‘association’’, ‘‘organization’’),
and 26 terms for geographic identifiers (‘‘International’’, ‘‘Euro-
pean’’, ‘‘Asian’’, ‘‘African’’, ‘‘American’’, ‘‘Australasian and
‘‘Oceanian’’ and other eligible countries’ names). Whenever we
came across a URL referring to a potentially pertinent society or
organization, we searched the entire directory. All the links in
these websites were further searched in order to reach any
additional pertinent societies or organizations. We recorded both
organizations with accessible webpages, as well as those whose
presence was mentioned in some URL, but either their link was
not functional (not working or under construction) or they did not
have a webpage that we could identify.
Identification of guidelines from pertinent organizations
Available websites from eligible societies and organizations were
scrutinized for any sort of clinical practice guidelines on any
subject matter (last update June 2009). Whenever there was
availability to perform an electronic search within the website, we
used the terms ‘‘guidelines’’ or ‘‘recommendations’’ or ‘‘position
statements’’ in English. For non-English websites, we translated
these terms into the language the website used. We could do this in
all languages except for 4 Japanese, 1 Swedish, 1 Finnish, 1 Danish
and 2 Dutch organizations.
Additionally, we perused some standard websites containing
information and/or links to guideline-related information, includ-
ing the National Guidelines Clearinghouse (NGC) (www.guideline.
gov), Guidelines International Network (G-I-N) (www.g-i-n.net),
National Institute for Health and Clinical Excellence (NICE)
(www.nice.org.uk), National Library of Health (www.library.nhs.
uk), New Zealand Guidelines Group (NZGG) (www.nzgg.org.nz),
Guidelines Advisory Committee (GAC) (www.gacguidelines.ca),
Australian National Health and Medical Research Council
(NHMRC) (www.nhmrc.gov.au) and the Scottish Intercollegiate
Guidelines Network (SIGN) (www.sign.ac.uk) in order to identify
additional potentially eligible guidelines. Finally, we also searched
PubMed with the strategy (guidelines OR recommendations OR
position statement) AND (breast OR mammary OR ovarian OR
ovary OR endometrial OR endometrium OR uterine OR cervical
OR cervix) AND (cancer OR carcinoma OR neoplasm OR
neoplasia).
Data extraction – eligible websites
For each pertinent society or organization with an accessible
website, we recorded its name, URL, continent and/or coun-
try(ies), specialty setting (medical oncology, radiation oncology,
surgical oncology, cancer research, or gynecology), and whether it
provided any clinical practice guidelines on any topic, regardless of
whether the guidelines had been developed by the specific society/
organization or some other source and similarly whether they
provided any eligible guideline addressing chemotherapy for one
or more of the eligible malignancies. Whenever any eligible
guidelines were available, we recorded whether recommendations
were freely accessible through the website and whether they
provided separate information developed by the society/organi-
zation itself or a link to another society/organization’s guidelines.
Data extraction – eligible guidelines
We recorded the exact wording and documentation regarding
the chemotherapy question from all the eligible guidelines that
mentioned anything on chemotherapy of advanced or recurrent
breast, ovarian, cervical and endometrial cancer. For cervical
cancer we separately recorded statements for stages III–IVa and
stage IVb since treatment and chemotherapy response differs
between these stages [13,16,17].
For each eligible guideline we addressed whether it provided
grading for the levels of evidence (and how this had been assessed)
and the strength of recommendations. We recorded aspects of the
production and implementation process for the guideline,
including involvement of multidisciplinary teams, search strategies,
reported funding, reported conflicts of interest, implementation
plans, and use of specific indicators to assess actual uptake. In
addition, we recorded the date of publication of the guidelines and
the date of publication of the most recent cited randomized trial or
meta-analysis. We addressed the utilization of randomized
evidence within the guidelines by recording whether guidelines
cited within their reference list any randomized trials and meta-
analyses pertinent to the chemotherapy question and, if so, how
many; and whether they made a comment on the need for more
randomized trials to provide sufficient guidance.
We also analyzed the outcomes discussed in the guidelines. We
addressed whether the guidelines provided any statement
regarding each of the following aspects of the effects of
chemotherapy: overall survival, disease-free interval or progres-
sion-free survival, response rate, recurrence rate, symptoms relief,
quality of life, toxicity profile and cost.
Finally, for each guideline and each type of advanced stage
malignancy, we recorded the position on whether chemotherapy
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‘‘against’’, if they clearly supported or clearly opposed, respective-
ly, the use of chemotherapy. We also recorded whether guidelines
in favor of chemotherapy were unequivocal about its overall
favorable benefit-risk ratio or offered any caveats.
Analyses
We evaluated whether guidelines for the different malignancies
differed among themselves in the use of grading, aspects of the
production and implementation process, timeliness, utilization of
randomized evidence, outcomes discussed, and stance towards use
of chemotherapy. Group comparisons for categorical variables used
Fisher’s exact test and group comparisons for continuous variables
used Mann-Whitney U test and analysis of variance. All analyses
wereconducted inSTATA SEversion 10.0.P-values aretwo-tailed.
Results
Eligible societies and organizations
Internet searches identified 220 societies/organizations. Addi-
tional searches performed in Pubmed and standard guideline
websites identified 4 more societies (1 and 3 respectively) that
provided any sort of clinical practice guidelines. Of the 224
entities, 105 were named ‘‘society’’, 51 ‘‘association’’, 8 ‘‘organi-
zation’’ and 60 had other names (alliance, board, centers,
coalition, college, consortium, council, federation, forum, founda-
tion, fund, group, institute, league, network, school and union).
There were 26 international, 77 intercontinental, and 153 national
entities covering a diverse array of countries and a range of
specialties (Table 1). Nine of the 224 did not have an accessible
webpage, 23 had no functional webpage at all, and 6 had
restricted access, thus 192 entities could be accessed and evaluated
for the presence of guidelines. Most of them (n=149) had a
webpage in English (Table 1).
Availability of any guidelines
Sixty-nine entities (31%) provided any sort of guidelines in their
websites (Table 1). For fifty-nine of them, at least one guideline
had been developed by the society/organization itself and in the
other 10 there were only links to other societies/organizations’
guidelines. Fifty two (75%) made their guidelines available in the
English language. The other 17 (25%) provided only guidelines in
other languages (4 Italian, 3 German, 3 French, 1 French and
German, 2 Dutch, 1 Norwegian, 1 Belgian and 1 Luxemburg).
Availability of guidelines did not vary per geographic location and
specialty setting (Table 1).
Eligible guidelines for chemotherapy in advanced
gynecological malignancies
Twenty entities provided any sort of guideline for chemotherapy
in advanced or recurrent gynecological cancer (Table 2). Among
them, 14 had developed at least one eligible guideline in English
language on their own. This included 8 entities with eligible
guidelines for breast cancer chemotherapy [18–25], 10 for ovarian
cancer [18–27], 8 for cervical cancer [18–22,25–27], and 8 for
endometrial cancer [18–22,26–28]. Five had developed guidelines
for chemotherapy for all these malignancies [18–22].
Grading and timeliness
A little over half of the guidelines covering the use of
chemotherapy in advanced gynecological malignancies addressed
the level of evidence available for the recommendations;
nonetheless no uniformity existed regarding the systems for
grading the level of evidence with 5 different systems being
utilized (Table 3). Furthermore, less than half provided a grading
system for the recommendations with no significant differences
across the examined malignancies (Table 3). The timeliness of the
Table 1. Distribution of organizations by location, society
and organization type.
Eligible
(accessible)
societies and
organizations
Number with
a website in
English
Number
with
guidelines
Continent
International 26 (22) 22 6
America(a) 35 (33) 32 16
Europe 16 (16) 16 8
Africa 4 (3) 3 0
Asia 7 (5) 5 1
Australia & New
Zealand
15 (14) 14 9
Country
USA (a) 32 (31) 31 16
Canada 13 (11) 11 3
North Europe
Sweden 3 (1) 1 1
Norway 6 (4) 2 1
Iceland 3 (2) 1 0
Finland 3 (1) 1 0
Denmark 5 (3) 3 0
Ireland 6 (3) 3 0
UK 11 (11) 11 5
Central & Western
Europe
Austria 6 (1) 1 2
Spain 7 (7) 3 1
Switzerland 10 (9) 4 2
France 13 (12) 2 4
Netherlands 8 (6) 1 2
Belgium 8 (8) 5 2
Luxemburg 1 (1) 0 1
Italy 9 (9) 3 5
Japan 9 (5) 5 0
Society type
Gynaecology 64 (53) 35 21
Overall cancer 53 (47) 38 17
Medical Oncology 22 (13) 10 4
Radiation oncology 23 (20) 15 6
Surgical Oncology 11 (10) 6 3
Cancer research 24 (23) 21 7
Other (b) 27 (26) 24 11
Total 224 (192) 149 69
(a)Continental American organizations include all USA national organizations
along with 2 other South American organizations.
(b)‘‘Other’’ refers to any society setting that does not belong to any of the above
specialty settings. This may include other specialty societies or other societies
such as guideline developers.
doi:10.1371/journal.pone.0020106.t001
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(Table 3). About two-thirds of the guidelines had been published
within the last 5 years and more than half within the last 2 years.
No significant difference was observed across guidelines for the
different malignancies neither for the date of publication of the
most recent cited trial or meta-analysis nor for the number of cited
trials or meta-analyses published within the last 5 years.
Key aspects of the production and implementation
process
Key aspects regarding the guideline production and implemen-
tation process did not significantly differ among analyzed
guidelines. More than 60% of the guidelines were stated to have
been developed by multidisciplinary teams of experts and only 1
guideline regarding endometrial cancer was developed by experts
from one medical field only (obstetricians/gynecologists), while in
the remaining guidelines it was unclear what experts exactly were
involved. A specific search strategy for the development of the
guideline was provided in less than 40%. None of the guidelines
reported industry-related funding, but often there was no
statement about who had potentially funded the guidelines;
moreover, conflicts of interest statements from panel members
were available in less than half of the guidelines. Finally, only few
of the guidelines provided an implementation plan of the
guidelines beforehand or reported that specific indicators were
considered in order to assess their actual uptake (Table 3).
Utilization of randomized evidence
The number of randomized trials cited within the guidelines
significantly differed among the malignancies tested (p,0.001)
(Table 3). Almost all the guidelines for breast and ovarian cancer
cited at least one randomized trial within their statements
compared to 50% or less of the guidelines for cervical and
endometrial cancer. It was also significantly more likely for meta-
analyses to be cited in the former than the latter group of
malignancies. However, the number of guidelines suggesting the
Table 2. Entities with guidelines for advanced stage gynecologic malignancies.
Entity Link Breast cancer Ovarian cancer Cervical cancer
Endometrial
cancer
American Cancer Society www.cancer.org Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
American College of Obstetricians and
Gynecologists
www.acog.org No guideline No guideline No guideline Own-developed
guideline
American Society for Therapeutic Radiology and
Oncology
www.astro.org Link to other Link to other Link to other Link to other
Association of Residents in Radiation Oncology www.arro.org Link to other Link to other Link to other Link to other
Australian Gynecological Cancer Society www.gcsau.org No guideline Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
British Association of Cancer United Patients www.cancerbackup.
org.uk
Link to other Link to other Link to other Link to other
Canadian Association of General Practitioners in
Oncology
www.cos.ca/cagpo Link to other Link to other Link to other Link to other
Cancer Council Australia www.cancer.org.au No guideline Own-developed
guideline
No guideline No guideline
European Society for Medical Oncology www.esmo.org Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
International Federation of Gynecology and
Obstetrics
www.figo.org No guideline Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
International Gynecologic Cancer Society www.igcs.org No guideline Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Medical Oncology Group of Australia www.moga.org.au Link to other Link to other Link to other Link to other
National Cancer Institute www.cancer.gov Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
National Comprehensive Cancer Network www.nccn.org Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
National Foundation for Cancer Research www.nfcr.org Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
National Health and Medical Research Council www.nhmrc.gov.au Own-developed
guideline
Own-developed
guideline
No guideline No guideline
National Institute of Health and Excellence www.nice.org.uk Own-developed
guideline
Own-developed
guideline
No guideline No guideline
Royal College of Obstetricians and Gynaecologists www.rcog.org.uk Link to other No guideline No guideline No guideline
Scottish Intercollegiate Guidelines Net work www.sign.ac.uk Own-developed
guideline
Own-developed
guideline
Own-developed
guideline
No guideline
Society of Gynecologic Oncologists www.sgo.org No guideline No guideline No guideline Own-developed
guideline
doi:10.1371/journal.pone.0020106.t002
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Type of cancer
P-
value
Breast
cancer
Ovarian
cancer
Cervical
cancer III–IVa
Cervical
cancer IVb
Endometrial
cancer
Number of available guidelines 81 0 88 8
Grading system of evidence and recommendations
Level of evidence* 5 (63%) 5 (50%) 4 (50%) 5 (63%) 4 (50%) 0.96
NCI PDQ ranking system (1) 1 1 1 1 1
SIGN grading system (2) 2 1 1 1 0
Grading system used by ASCO (3) 1 1 1 1 1
NHMRC grading system (4) 1 1 0 0 0
US Preventive Services task force (5) 0 0 0 1 1
Not described (6) 0 1 1 1 1
Grade of recommendation 3 (38%) 3 (30%) 3 (38%) 3 (38%) 2 (25%) 1.00
Key aspects for guidelines production process
Guidelines’ panels 0.88
Multidisciplinary 6 (75%) 7 (70%) 5 (62%) 5 (62%) 5 (62%)
Only one discipline 0 0 0 0 1 (13%)
Unclear 2 (25%) 3 (30%) 3 (38%) 3 (38%) 2 (25%)
Description of the search strategy used 1.00
Yes 3 (38%) 3 (30%) 2 (25%) 2 (25%) 2 (25%)
No 5 (62%) 7 (70%) 6 (75%) 6 (75%) 6 (75%)
Funding 0.95
Non-industry or no funding 6 (75%) 6 (60%) 5 (62%) 5 (62%) 4 (50%)
Not reported 2 (25%) 4 (40%) 3 (38%) 3 (38%) 4 (50%)
Reporting of members’ conflicts of interest 0.95
Yes 4 (50%) 4 (40%) 3 (38%) 3 (38%) 2 (25%)
No 4 (50%) 6 (60%) 5 (62%) 5 (62%) 6 (75%)
Implementation plan described 0.64
Yes 4 (50%) 4 (40%) 2 (25%) 2 (25%) 1 (13%)
No 4 (50%) 6 (60%) 6 (75%) 6 (75%) 7 (77%)
Performance indicators to assess guidelines uptake 0.64
Yes 4 (50%) 4 (40%) 2 (25%) 2 (25%) 1 (13%)
No 4 (50%) 6 (60%) 6 (75%) 6 (75%) 7 (77%)
Timelines of guidelines updates
Guideline publication date (median and range) 2008
(2001–2009)
2007
(2001–2009)
2008
(2001–2009)
2008
(2001–2009)
2008
(2001–2009)
0.97
Guidelines published within the last 5 years 6 (75%) 6 (60%) 7 (88%) 7 (88%) 6 (75%) 0.66
Guidelines published within the last 2 years 5 (63%) 5 (50%) 5 (63%) 5 (63%) 4 (50%) 0.97
Date of the most recent cited randomized trial -
or meta-analysis (median and range)
2008
(2000–2008)
2006
(1996–2007)
2005
(1999–2007)
2005
(1985–2007)
2006
(2004–2006)
0.22
Cited randomized trial or meta-analysis
published within the last 5 years
6 (75%) 5 (50%) 3 (38%) 3 (38%) 4 (50%) 0.81
Utilization of randomized evidence
Citation of any randomized trial 7 (88%) 9 (90%) 3 (38%) 4 (50%) 4 (50%) 0.09
Number of cited randomized trials (mean) 11.88 9.9 1.63 1.25 1.38 ,0.001
Citation of any meta-analysis 6 (75%) 3 (30%) 2 (25%) 1 (13%) 0 0.013
Number of meta-analyses (mean) 1.38 1.1 0.63 0.13 0 0.19
Need for more randomized trials 6 (75%) 7 (70%) 3 (38%) 5 (63%) 4 (50%) 0.62
*the reference sources for the assignment of levels of evidence are as follows:
(1)http://www.cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthProfessional/page2;
(2)ScottishIntercollegiateGuidelines Network.MethodologyReview Group.Report on the reviewof themethod of gradingguideline recommendations.Edinburgh: SIGN; 1999.;
(3)Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102:305S–311S, 1992 (suppl 4);
(4)National Health and Medical Research Council (NHMRC). How to Use the Evidence: Assessment and Application of Scientific Evidence. Canberra, Australia: NHMRC; 2000;
(5)http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual4.htm;
(6)FIGO guidelines present a grading system for level of evidence (A–D) without specifying which system used.
doi:10.1371/journal.pone.0020106.t003
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malignancies tested.
Discussion of outcomes
Statements regarding overall survival were provided in most
guidelines with no significant difference for the discussion of this
outcome for the different malignancies (Table 4). Conversely,
discussion of outcomes such as disease-free survival, response rate,
symptoms relief, quality of life, and toxicity of medications
significantly differed across malignancies with breast and ovarian
cancer guidelines providing more frequently such statements
compared to cervical and endometrial cancer. In particular, none
of the guidelines on stage III–IVa cervical cancer or endometrial
cancer touched on issues of costs related to chemotherapy, whereas
less than 40% addressed issues regarding toxicity (Table 4).
Stance towards use of chemotherapy
None of the analyzed guidelines for these advanced stage
gynecological malignancies were against using chemotherapy in these
patients. All guidelines seemed to endorse explicitly or implicitly the use
of some chemotherapy, at least in some settings and patients. No major
caveats were raised for breast, ovarian, and stage III–IVa cervical
cancer [18–27]. For stage IVb cervical cancer three guidelines had
some caveats stating that treatment should be individualized (‘‘Patients
with stage 4 disease have their treatment very much individualized
depending on the distribution of the disease’’ [27]) or that no standard
chemotherapy is available (‘‘No standard chemotherapy treatment is
available for patients with stage IVB cervical cancer that provides
substantial palliation’’ [21] and ‘‘There is no good single chemotherapy
approach that can improve the length of survival in patients with
metastatic cervical cancer. Unfortunately, these chemotherapies
typically work for only a few months before the cervical cancer begins
to grow again. Most patients ultimately succumb to cancer and better
treatment strategies are clearly needed’’ [22]). For endometrial cancer,
3 guidelines only presented data from trials without clear supportive
statements that patients would benefit from chemotherapy [20,21,27].
All guidelines, with the exception of 1 on endometrial cancer and 1 on
cervical cancer, also presented inf o r m a t i o no na n d / o re n d o r s e m e n to f
specific chemotherapeutic agents.
Discussion
Our evaluation identified over 200 cancer and gynecological
societies and organizations that operate at international or
national level. This is an impressive number and it offers a picture
of flourishing professional activity. Many of these organizations
have very extensive membership, organize large meetings, and
have substantial influence upon their members, subscribers, and
visitors to their websites [29–32]. Yet only a third of these
societies/organizations provided any sort of guidelines within their
websites. When it comes to specific questions of interest, such as
the use of chemotherapy in advanced stage gynecological
malignancies that we analyzed here, only one in ten societies/
organizations offered such guidelines, and an even smaller number
of them had developed their own guidelines. Therefore, a few
professional entities seem to dominate the literature of these
influential documents; some others adopt what is produced by
others, while the majority is unfamiliar with the guideline concept.
Important aspects of the production and implementation process
of these guidelines were often unstated. The number of available
guidelines did not depend on the bulk of available evidence or the
strength of the evidence in favor of chemotherapy. A similar
number was available for advanced breast and ovarian cancer
where hundreds of trials have been published [11,12] as well as for
advanced endometrial and cervical cancer where the evidence is
more limited [13,14].
The analyzed guidelines did not differ across malignancies in
terms of their adoption of levels of evidence, grading of
recommendations, and aspects of production and implementation
process, or timeliness. Their performance in this regard on average
is comparable to guidelines from other fields [33–40] and there is
substantial room for improvement. The use of levels of evidence
and grades of recommendation may be enhanced if this approach
is adopted centrally for all guidelines produced by an organization,
e.g. the ACC/AHA guidelines in cardiology always use this
approach [9]. Timeliness of guidelines updates also constitutes a
serious issue [8] and it can affect the reliability of these documents,
especially for fields where evidence changes rapidly. There is large
variability across medical fields and across clinical questions of
interest in the rate with which new evidence accumulates and
changes the overall picture [41–44]. For all the malignancies
analyzed here, most guidelines were updated within the last 5
years. This is probably an acceptable frame for these fields,
although it is still possible that a window of 5 years may miss some
important recent randomized evidence on specific regimens. One
may need to re-assess the acceptable time frame as new evidence
arises, but most guidelines developers lack formal procedures for
updating their guidelines [45].
Table 4. Outcomes discussed in guidelines for chemotherapy for advanced gynecological malignancies.
Type of cancer P-value
Breast
cancer
Ovarian
cancer
Cervical
cancer III–IVa
Cervical
cancer IVb
Endometrial
cancer
Number of available guidelines 81 0 888
Overall survival 7 (88%) 8 (80%) 5 (63%) 5 (63%) 5 (63%) 0.68
Disease-free survival 7 (88%) 8 (80%) 2 (25%) 3 (38%) 3 (38%) 0.033
Response rates 7 (88%) 10(100%) 3 (38%) 5 (63%) 5 (63%) 0.024
Recurrence 4 (50%) 6 (60%) 7 (88%) 8(100%) 7 (88%) 0.092
Symptoms relief 4 (50%) 8 (80%) 1 (13%) 6 (75%) 1 (13%) 0.005
Quality of life 6 (75%) 5 (50%) 0 5 (63%) 0 0.001
Toxicity 7 (88%) 8 (80%) 3 (38%) 2 (25%) 3 (38%) 0.039
Costs 3 (38%) 2 (20%) 0 0 0 0.054
doi:10.1371/journal.pone.0020106.t004
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malignancies in the extent of utilization of randomized evidence
(citation of randomized trials and meta-analyses). This is not
surprising, given that there are far more randomized trials and
meta-analyses performed for advanced breast and ovarian cancer
than for cervical and endometrial cancer. The conduct of
randomized trials may be encouraged in fields where results of
chemotherapyhave been favorable (breastand ovariancancer),while
investigators may feel less enthusiastic to perform more trials in fields
where chemotherapy has shown equivocal results with no clear
benefits (cervical and endometrial cancer). Most of the analyzed
guidelines cited at least one randomized trial. It has been observed
across diverse fields that utilization of randomized evidence has
increased in guidelines over time [46]. Nevertheless, most of the
analyzed guidelinescited few randomized trialsofthoseperformed on
the respective questions. Therefore use of randomized evidence
seems to remain eclectic in these documents.
Even though the benefits of chemotherapy vary a lot among the
malignancies that we analyzed, all of the guidelines explicitly or
implicitly endorsed the use of chemotherapy for all malignancies.
This is fully justified for breast, ovarian and possibly stage III–IVa
cervical cancer, where the available evidence shows that chemother-
apy has substantial benefits [11,12,16,17]. Conversely, chemotherapy
has shown no convincing benefits, especially for hard outcomes such
as survival, for stage IVb cervical and advanced endometrial cancer
[13,14]. However, only 3 of the 8 guidelines for each of the latter
t y p e so ft u m o r sh a ds o m ec a v e a t sa n dw e r en o to p e n l yc o m m i t t e dt o
widespread use of chemotherapy in these patients.
Furthermore, outcomes such as secondary effectiveness mea-
sures and toxicity profile were addressed more frequently in breast
and ovarian cancer, whereas cervical and endometrial cancer
guidelines totally omitted statements regarding quality of life and
costs of chemotherapy and were less likely to discuss also these
other outcomes. Reporting of these issues is important for one to
adopt or decline the use of specific treatments. Especially in
tumors in which chemotherapy does not appear to offer clear
benefit in terms of overall survival, secondary effectiveness
outcomes, toxicity, quality of life and cost may be the only data
available to justify or not its use. Omission of statements regarding
these outcomes in these malignancies may mislead conclusions and
may explain the generally favorable stance of the guidelines
towards chemotherapy even for advanced cervical and endome-
trial cancer.
One may argue that scientific societies may sometimes have
considerable conflicts that pose obstacles in creating objective
guidelines. For example, if professionals benefit from administer-
ing specific interventions to patients, their societies may not be
unbiased enough to recommend that patients should not be
treated with specific interventions (such a recommendation would
reduce the volume of clientele and financial gains of these
professionals). The ubiquitous recommendation of chemotherapy
for all the examined types of cancers (regardless of whether it is
effective or not) raises such concerns. An unbiased, intersocietal
and interprofessional collaborative approach may be useful in this
regard.
Some limitations of our work should be discussed. First, for 32
entities we could not find access to a website. However, it is not
very likely that these entities would have guidelines of their own,
let alone high-quality ones. Second, it is possible that some entities
may not have published guidelines on chemotherapy, if they
deemed that chemotherapy is ineffective and thus not worth
addressing. However, we found a similar number of guidelines for
tumors where chemotherapy is very effective and for those where
it is more controversial. Third, there are no established validated
searches for unearthing professional societies and organizations
and some of them may have been missed by our searches.
However, given the multiple layers of our search, it is unlikely that
prominent entities were missed.
In conclusion, our evaluation suggests that guidelines from
professional gynecological and cancer societies and organizations
have substantial room for improvement. Recommendations
should be based on solid scientific evidence with balanced
discussion of all potential benefits, harms and costs of the proposed
interventions.
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